Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Infant Aphakia Treatment Study (IATS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Alcon Laboratories
Bausch & Lomb Incorporated
BSN-JOBST Inc.
Eye Care and Cure
Information provided by (Responsible Party):
Scott R Lambert, MD, Emory University
ClinicalTrials.gov Identifier:
NCT00212134
First received: September 13, 2005
Last updated: February 25, 2013
Last verified: February 2013
  Purpose

The primary purpose is to determine whether infants with a unilateral congenital cataract are more likely to develop better vision following cataract extraction surgery if they undergo primary implantation of an intraocular lens or if they are treated primarily with a contact lens. In addition, the study will compare the occurrence of postoperative complications and the degree of parental stress between the two treatments.


Condition Intervention Phase
Congenital Cataract
Device: optical correction of infant aphakia with Contact Lens or Intraocular Lens
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Infant Aphakia Treatment Study (IATS)

Resource links provided by NLM:


Further study details as provided by Emory University:

Primary Outcome Measures:
  • Visual Acuity [ Time Frame: 12 months of age and 4.5 years of age ] [ Designated as safety issue: No ]
    Visual acuity was measured by objective testing procedures at 12 months. There was no statistical difference in the vision in the study eye between the Contact lens and the IOL groups. Subjective VA measures will be done at 4.5 years.


Secondary Outcome Measures:
  • Complications [ Time Frame: 12 months of age and to 5 years of age ] [ Designated as safety issue: Yes ]
    There were more intra- and post-operative complications in the IOL group.

  • Parenting Stress [ Time Frame: 12 months of age and to 5 years. ] [ Designated as safety issue: No ]
    not yet published


Enrollment: 114
Study Start Date: December 2004
Estimated Study Completion Date: May 2014
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: aphakic contact lens

optical correction of infant aphakia with aphakic Contact lens

INTERVENTION: aphakic contact lens

Device: optical correction of infant aphakia with Contact Lens or Intraocular Lens
optical correction of infant aphakia with Intraocular Lens or Contact lens
Other Names:
  • Silsoft or RGP aphakic contact lenses
  • Alcon SA60 or MA60 silicon aphakic intraocular lens
Experimental: aphakic intraocular lens

optical correction of infant aphakia with aphakic Intraocular Lens

INTERVENTION: aphakic intraocular lens

Device: optical correction of infant aphakia with Contact Lens or Intraocular Lens
optical correction of infant aphakia with Intraocular Lens or Contact lens
Other Names:
  • Silsoft or RGP aphakic contact lenses
  • Alcon SA60 or MA60 silicon aphakic intraocular lens

Detailed Description:

Intraocular lenses are now a commonly accepted treatment for cataracts in older children and are used increasingly in younger children and infants. Intraocular lenses are superior to contact lenses in that they more closely replicate the optics of the crystalline lens, do not require daily ongoing care, and ensure at least a partial optical correction at all times. The simplicity and improved visual outcome of an intraocular lens correction may make caring for a child with a unilateral congenital cataract less stressful for parents. However, contact lenses remain the accepted treatment for children under 1 year of age due to concerns about the long-term safety of intraocular lenses and the potential for a large myopic shift developing in these eyes as they grow. Contact lenses provide excellent visual results in infants treated for bilateral congenital cataracts; however, two-thirds of infants treated with contact lenses for unilateral congenital cataracts remain legally blind in their aphakic eye. These poor visual outcomes are usually ascribed to competition from the sound eye and poor compliance with patching and contact lens wear regimens. Data from our pilot study and the literature suggest that superior visual results can be obtained if an intraocular lens is used to correct unilateral aphakia during infancy, but these eyes will experience more complications. Intraocular lenses will be increasingly implanted in infants regardless of whether or not we perform this trial. By performing this clinical trial, we can determine if the higher rate of complications with intraocular lenses is offset by improved visual outcome and decreased parenting stress.

The Infant Aphakia Treatment Study (IATS) is a multi-center randomized clinical trial comparing intraocular lens and contact lens correction for monocular aphakia. Infants will be enrolled over a 4 year period. Infants 28 to 210 days of age with a visually significant cataract in one eye are eligible. Cataract surgery will be performed in a standardized fashion by a surgeon who has been certified for the study. Surgery consists of a lensectomy, posterior capsulotomy, and anterior vitrectomy. Infants will be randomized at the time of surgery to one of two treatment groups. Infants randomized to the intraocular lens group will have an intraocular lens implanted into the capsular bag. Spectacles will subsequently be used to correct the residual refractive errors. Infants randomized to the contact lens group will be fitted with a contact lens immediately after surgery. Both groups will receive the same patching therapy and follow-up. All children will be examined by Investigators at fixed intervals using standard protocols with the major endpoint assessed at age 12 months by a Traveling Vision Examiner.

We are currently in a continuation of this project (beyond 5 years) in order to perform subjective visual acuity testing at 4.5 years of age and 5 year follow-up vision and ocular health exams on all children.

We will submit a competitive application to be able to have a single visit by the patients in this cohort when they reach 10 years of age. This will be past the amblyogenic period and permit a more accurate comparative assessment of visual acuity and ocular health between the primary intervention groups.

  Eligibility

Ages Eligible for Study:   up to 210 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Visually significant unilateral congenital cataract (central opacity equal to or greater than 3 mm in size).
  • Cataract surgery performed when the patient is 28 to 210 days of age and at least 41 post-conceptional weeks.

Exclusion Criteria:

  • The cataract is known to be acquired from trauma or as a side-effect of a treatment administered postnatally such as radiation or medical therapy.
  • A corneal diameter less than 9 mm measured in the horizontal meridian using calipers.
  • An intraocular pressure of 25 mm Hg or greater in the affected eye measured with a Perkins tonometer, tonopen, or pneumatonometer.
  • Persistent fetal vasculature (PFV) causing stretching of the ciliary processes or a tractional retinal detachment.
  • Active uveitis or signs suggestive of a previous episode of uveitis such as posterior synechiae or keratic precipitates.
  • The child is the product of a pre-term pregnancy (<36 gestational weeks). Screening for prematurity will be based on the clinician's best assessment of gestational age. If a physician is uncertain regarding the gestational age, review of medical records or contact with the pediatrician and/or obstetrician should be used to confirm gestational age at delivery. Unless a clinician is uncertain as to whether a child was born at less than 36 weeks or not, confirmation of gestational age via medical record review may be delayed until after enrollment.
  • Retinal disease that may limit the visual potential of the eye such as retinopathy of prematurity.
  • Previous intraocular surgery.
  • Optic nerve disease that may limit the visual potential of the eye such as optic nerve hypoplasia.
  • The fellow eye has ocular disease that might reduce its visual potential.
  • The child has a medical condition known to limit the ability to obtain visual acuity at 12 months or 4 years of age.
  • Refusal by the Parent/Legal Guardian to sign an informed consent or to be randomized to one of the two treatment groups.
  • Follow-up of the child is not feasible because the child would not be able to return for regular follow-up examinations and the outcome assessments (e.g. transportation difficulties, relocation, etc.).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00212134

Locations
United States, Florida
Miami Children's Hospital
Miami, Florida, United States, 33155
United States, Georgia
Emory Eye Center
Atlanta, Georgia, United States, 30322
United States, Indiana
Indiana University Medical Center
Indianapolis, Indiana, United States, 46202-5175
United States, Massachusetts
Harvard University
Boston, Massachusetts, United States, 02115
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455-0501
United States, North Carolina
Duke University Eye Center
Durham, North Carolina, United States, 27710
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239-4197
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425-2236
United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232-8808
United States, Texas
Pediatric Ophthalmology, P.A.
Dallas, Texas, United States, 75225
Baylor University
Houston, Texas, United States, 77030
Sponsors and Collaborators
Emory University
Alcon Laboratories
Bausch & Lomb Incorporated
BSN-JOBST Inc.
Eye Care and Cure
Investigators
Study Chair: Scott Lambert, MD Emory University Eye Center
  More Information

Additional Information:
No publications provided by Emory University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Scott R Lambert, MD, Professor, Emory University
ClinicalTrials.gov Identifier: NCT00212134     History of Changes
Other Study ID Numbers: NEI-108, U10EY013272, EY013287, EY013272
Study First Received: September 13, 2005
Last Updated: February 25, 2013
Health Authority: United States: Federal Government
United States: Food and Drug Administration

Keywords provided by Emory University:
cataract surgery
intraocular lens
contact lens
infants
aphakia

Additional relevant MeSH terms:
Aphakia
Cataract
Eye Diseases
Lens Diseases

ClinicalTrials.gov processed this record on November 25, 2014